Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mini-hyperCVD
- Development stage
- Unknown
- Lead developer
- University of Chicago Medicine
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
mini-hyperCVD is a low-intensity chemotherapy regimen primarily used for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), particularly in older adults or patients unfit for intensive chemotherapy. It is a dose-reduced modification of the standard hyper-CVAD regimen. The regimen typically omits anthracyclines (such as doxorubicin) and features reduced doses of cyclophosphamide, dexamethasone, methotrexate, and cytarabine to improve tolerability while maintaining efficacy. It is structured into alternating cycles: Part A consists of cyclophosphamide, vincristine, and dexamethasone, while Part B consists of high-dose methotrexate and cytarabine. In contemporary clinical trials, mini-hyperCVD is frequently evaluated as a backbone regimen in combination with targeted agents such as venetoclax, blinatumomab, inotuzumab ozogamicin, or capivasertib.
- Other names
- mini-hyper-CVDlow-intensity hyper-CVD
02
Targets
DNADNA polymerase familyDHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on mini-hyperCVD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mini-hyperCVD.